Amgen AMGN
-
Timing Is Everything Vs. Seductive Hype
… the mid-1980s discoveries in biotechnology were revealed and investors piled-into many new companies like Genentech and Amgen . But the technology was yet to produce profits for many years to come. Mutual fund companies devoted some funds to this new …
-
VHT Vanguard Health Care ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… investments include managed-care firms such as UnitedHealth Group UNH and WellPoint WLP, biotech companies such as Amgen AMGN , and medical-device firms such as Medtronic MDT and Covidien COV. The fund's heavy exposure to Big Pharma shouldn …
-
Interest Growing In Cancer Stem Cell Biotechs
By A John Hodge : In two weeks more than 25,000 cancer specialists will come together at the annual ASCO meeting in Chicago. There will be 1,000's of scientific abstracts released, and investors will pay close attention as the meeting always produces a number of market moving developments. I am ...
-
Medgenics Moving In Record Time
… Biopumps in development, looks to eliminate frequent, costly and inconvenient injections of erythropoietin (EPO). Amgen Inc. ( AMGN ) has owned this space for years and medicine is ready for a change. Our FDA, known for its sluggishness and bad …
-
Investment Choices For Melanoma Awareness Month
By Amy Baldwin : Affecting more than 65,000 new patients and claiming about 11,000 lives annually, melanoma treatment represents a huge unmet need. With the knowledge that sun exposure is responsible for the cause of about two-thirds of all melanoma cases, May has been dubbed " melanoma awareness
-
Critical Success Factors For The Immunotherapy Race
By Andrew J. Norris : Previously we covered differing approaches taken by emerging and innovative publicly traded companies in the cancer vaccine space. This article will probe another aspect of performance that is more practical: critical success factors for dominating companies that will emerge
-
New Morningstar Analyst Report - Hospira, Inc.
… large molecules derived from living organisms. Biosimilars coming off patent over the next decade for drugs such as Amgen 's AMGN Epogen and Roche's RHHBY Rituxan create big opportunities for generic drug manufacturers. However, the very high …
-
2 Healthcare Companies To Buy, 2 To Hold
… better investments than others. Hold Amgen ( AMGN ). It recently traded at $70 ..... 15% a year over the next five. Amgen has an operating margin of 27.30 ..... 31 times its forward earnings. Amgen looks pretty attractive but other …
-
New Morningstar Analyst Report - Teva Pharmaceutical Industries, Ltd.
… guidelines are still being finalized, Teva has already filed an application in the U.S. for a biosimilar version of Amgen 's AMGN Neupogen. Teva and others have had mixed success and slow market share gains with their European biosimilar launches …
-
New Morningstar Analyst Report - Watson Pharmaceuticals Inc.
… announced a development partnership with Amgen AMGN for biosimilars, which are near equivalent ..... think Watson's partnership with Amgen places the company among the few participants ..... remain a few years away. Watson and Amgen have not disclosed their biosimilars …